{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024193","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.641841+00:00","generated_at":"2026-06-21T23:50:32.855006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Candel Therapeutics Q3 net loss $8.7M; cash $77.2M, runway into Q1 2024; UPenn CAR-T partnership","bullets":["Net loss $8.7M vs $16.2M in Q3 2021; improvement driven by non-cash warrant liability changes.","Cash and equivalents $77.2M as of Sep 30, 2022; expected to fund operations into Q1 2024.","R&D expenses $5.4M, G&A $3.5M; increases due to higher headcount, clinical studies, and public company costs.","European Commission granted orphan drug designation for CAN-2409 in glioma; phase 3 protocol submitted.","Partnered with UPenn Center for Cellular Immunotherapies to study viral immunotherapy + CAR-T in solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024193","json":"https://secwatch.observer/filing/0000950170-22-024193.json","markdown":"https://secwatch.observer/filing/0000950170-22-024193.md","text":"https://secwatch.observer/filing/0000950170-22-024193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017022024193/0000950170-22-024193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017022024193/cadl-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:50:32.855006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"baf3fe000dc6275269e98be1cb879d2b968e90c0","claim":"Candel Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $31,000, net income $8.7 million.","evidence_excerpt":"Research and Development Service Revenue, related party: Research and Development Service Revenue, related party, for the third quarters ended September 30, 2022 and 2021 was $31,000. Research and Development Expenses: Research and development expenses were $5.4 million for the quarter ended September 30, 2022 compared to $5.3 million for the comparable","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017022024193/0000950170-22-024193-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$31,000"},{"label":"Net income","value":"$8.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}